EGFR and non-small cell lung carcinoma: The initial approval of osimertinib for EGFR T790M-positive NSCLC was based on the results of the AURA3 trial [15], which demonstrated significantly longer median PFS with osimertinib than with platinum therapy plus pemetrexed (10.1 months vs. 4.4 months, respectively).